MAP2K7 and melanoma: Despite recent successes in antitumor growth activity (including our study) with BRAF/MEK/CDK4/6 inhibition in BRAFV600E-mutant melanomas [44], some may argue against using the triple therapeutic agent following recent reports of sustained clinical OS and progression-free survival (PFS) rates lasting up to five years in a proportion of melanoma patients [47, 48].